- Home
- BRAG vs SKYE Comparison
BRAG vs SKYE Comparison
Compare BRAG & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRAG | SKYE |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5M | 44.9M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BRAG | SKYE |
|---|---|---|
| Price | $1.53 | $0.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.00 | ★ $14.75 |
| AVG Volume (30 Days) | 25.7K | ★ 205.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 86.41 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $0.68 |
| 52 Week High | $4.82 | $5.75 |
Technical Indicators
Market Signals| Indicator | BRAG | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 29.22 | 48.50 |
| Support Level | N/A | $0.68 |
| Resistance Level | $2.77 | $0.83 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 12.99 | 63.95 |
Price Performance
Historical ComparisonAbout BRAG Bragg Gaming Group Inc.
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The Company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic, and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from the Netherlands and the rest from Curacao, Malta, the United States, Croatia, and other regions.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.